Jan 20,2022

Berlin-based Cara Care app approved as German DiGA

The German Federal Institute für Drugs and Medical Devices (BfArM) has added a new digital therapeutic to its digital health applications (DiGA) directory for public reimbursement. Cara Care is the first DiGA that addresses gastroenterological issues and widespread digestive health problems such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), food and reflux intolerances.

PRODUCT

#reimbursement

#pdt

View Analyst & Ambassador Comments
Go to original news
Jan 26,2022

Oklahoma Health Care Authority and Pear Therapeutics Enter into Value-Based Agreement for reSET® and reSET-O®

Pear Therapeutics, Inc. (Nasdaq: PEAR), the parent company of Pear Therapeutics (US), Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today a value-based agreement with Oklahoma Health Care Authority (OHCA) to provide access to Pear’s PDTs reSET® and reSET-O® to help fight the growing substance and opioid addiction crisis. Effective January 1, 2022, reSET and reSET-O will be made available to Oklahomans enrolled in Oklahoma Medicaid, commonly known as SoonerCare. Pear’s products reSET and reSET-O are the first and only FDA-authorized, safe and effective PDTs for the treatment of substance use disorder and opioid use disorder, respectively.

COLLABORATION PARTNERSHIP

#insurance

#reimbursement

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 31,2022

Pfizer to promote Alex Therapeutics' smoking cessation app

Pfizer has inked a deal with the Swedish digital therapeutic platform developer Alex Therapeutics to help study and launch a smartphone app for combating nicotine addiction. Prior to commercialization, Pfizer’s Germany-based division will first help with clinical validation of the smoking cessation program, dubbed Elia. The initial goal is to develop a prescription app that would be reimbursable under Germany’s digital healthcare regulations.

COLLABORATION PARTNERSHIP

#product & service

#pdt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Feb 04,2022

Digital musculoskeletal care is booming. Where does the market go from here?

Musculoskeletal care is a big problem for the U.S. healthcare system, digital health companies say. Disorders are common and expensive to treat, but care that could cut down those high costs is inaccessible to many who need it. Mark Luck Olson, CEO of RecoveryOne, argues surgeries are too common in the U.S. and that intervening early with physical therapy would save money. But the goal for digital musculoskeletal care should be more than just moving a physical therapy appointment to a virtual environment.

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Feb 04,2022

How Digital Therapeutics Will Evolve in 2022 and Beyond

As healthcare delivery has gone virtual, so have the clinical treatments themselves, resulting in a new category of medical interventions: digital therapeutics. This new category of medicine has been growing over the past decade, steadily adding research and real-world evidence to support its use. As digital therapeutics become validated and get incorporated into clinical care, another question arises: how will this category evolve alongside the pandemic in 2022 and beyond?

#pdt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Feb 10,2022

Pear Therapeutics Announces State of Michigan to Fund Access to Prescription Digital Therapeutics for Substance Use and Opioid Use Disorders

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today that the state of Michigan will provide funding towards access to Pear’s PDTs reSET® and reSET-O® for the treatment of substance use disorder (SUD) and opioid use disorder (OUD), respectively.

PRODUCT

#reimbursement

#pdt

View Analyst & Ambassador Comments
Go to original news
Feb 18,2022

Report names Europe’s digital health app reimbursement leaders and laggards

The reimbursement channel for digital health apps in Europe has traditionally been long and complex. But new analysis from Research2Guidance (R2G) predicts reimbursement opportunities will improve significantly over the next few years. An R2G report has categorised European countries into groups of leaders, fast followers, certifiers and laggards, based on their public health insurance system’s reimbursement process status. Leading the way are Germany, Belgium and France which have standardised reimbursement processes for digital health applicatoins and therapeutics in place or soon to be launched.

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Feb 28,2022

Pear Therapeutics advances in efforts to get CMS to cover prescription digital therapeutics

Pear Therapeutics (NSDQ:PEAR) announced that the Centers for Medicare & Medicaid Services (CMS) established new coding relevant to its prescription digital therapeutics (PDTs). CMS established a new Level II Healthcare Common Procedure Coding System (HCPCS) code to describe prescription digital behavioral therapy — FDA-cleared — per course of treatment, which extends to PDTs including Pear’s reSET, reSET-O and Somryst. The CMS coding decision, published on Feb. 16, 2022, becomes effective on April 1, 2022. The code for prescription digital behavioral therapy is “A9291.”

PRODUCT

#pdt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Mar 07,2022

HelloBetter’s digital therapy “Vaginismus Plus” is available free of charge on prescription in Germany

HelloBetter, a Berlin-based digital health company, has developed a digital therapy programme, with online support from psychologists and psychotherapists, that effectively reduces the occurrence of painful penetration. The effectiveness of HelloBetter Vaginismus Plus has been demonstrated in two clinical studies and this digital medical product is now available on prescription and free of charge across Germanyn through the DiGA.

PRODUCT

#reimbursement

#pdt

View Analyst & Ambassador Comments
Go to original news
Mar 09,2022

The application of Tilak Healthcare for eye health will be reimbursed by Social Security

The French start-up Tilak Health announces the reimbursement of its OdySight application, an eye health monitoring application. It is part of article 51, created in 2018 as part of the social security financing law, which allows experimentation with new organizations in the health sector. Its use makes it possible to remunerate the doctors prescribing the application. Developed by the start-up Tilak Healthcare, this application offers visual tests and therapeutic games to monitor the state of health of patients with ocular pathologies. It is currently used by more than 400 retinologists and has been prescribed to 3,500 patients in France.

PRODUCT

#reimbursement

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to REIMBURSEMENT